SERPINE1 and chronic myelogenous leukemia, BCR-ABL1 positive: Indeed, the selective targeting of PAI-1 with several small molecule inhibitors increased the susceptibility of chronic myeloid leukemia stem cells (CML-LSCs) to imatinib chemotherapy in a mouse model [162].